Effects of Astragaloside IV and Formononetin on Oxidative Stress and Mitochondrial Biogenesis in Hepatocytes

Area of Science:

• Mitochondrial Biology
• Oxidative Stress Research
• Pharmacology

Background:

• Overproduction of reactive oxygen species (ROS) leads to hepatocyte dysfunction and liver damage.
• Sirtuin-3 (SIRT3), a mitochondrial deacetylase, is crucial for regulating mitochondrial function and antioxidant defense.
• Astragaloside IV (AST-IV) and formononetin (FMR) are natural compounds with potential therapeutic properties.

Purpose of the Study:

• To investigate the antioxidative effects of AST-IV and FMR in relation to SIRT3.
• To explore the impact of these compounds on ROS levels, cell proliferation, and antioxidant enzyme activity in hepatocytes.
• To elucidate the underlying mechanism involving SIRT3 activation and mitochondrial biogenesis.

Main Methods:

• Hepatocytes (AML12) were treated with AST-IV and FMR under conditions of oxidative stress induced by tert-butyl hydroperoxide (t-BHP).
• Cell proliferation, ROS levels, superoxide dismutase (SOD) activity, and transcriptional levels of antioxidant genes (Sod2, Cat, GPX1) were measured.
• Activation of key signaling pathways like PGC-1α and AMPK, as well as SIRT3 expression, were assessed.

Main Results:

• Combined pre- and post-treatment with AST-IV or FMR increased cell proliferation and rescued cells from oxidative damage.
• Significant reduction in ROS levels was observed with combined AST-IV and FMR treatments at specific concentrations.
• AST-IV and FMR treatments upregulated SOD activity and antioxidant gene expression, indicating enhanced ROS detoxification.
• These compounds activated PGC-1α, AMPK, and SIRT3 expression in hepatocytes exposed to oxidative stress.

Conclusions:

• AST-IV and FMR exert antioxidative effects by inducing SIRT3 protein expression and activating antioxidant mechanisms.
• These agents promote mitochondrial biogenesis and enhance mitochondrial function, contributing to their protective effects.
• AST-IV and FMR show promise as SIRT3 modulators for treating oxidative liver injury.